I have been playingNAVB, PATH for FDA approval, and DCTH. While NAVB and DCTH are still waiting for their approval dates, I did make out on PATH run up from $3.00to $3.70-$3.80. I have watched this stock drop from the $2.40 area back down to the "comfort zone" of $2.80. Many of these pharma stock are run up then brought back down a month before the news. With panel vote coming in later March, this is working out to perfection.
I am just wondering how low they will take the stock in the next couple weeks or will they start to run the price back up again. Seems like trials have been working and with the FDA speed up for approval and the trials looking good, the adcom panel vote should be good for effectiveness and safety.profile. Do you thin k this has a chance of going lower because the announcement of the date has not been said yet. Another move from $1.80 to $2.40 is a good 33% move. If the MM's really want to make a profit, they could take it down to $1.50-$1.60 for a 50% move back upwards.
Should have said the "comfort zone " of $1.80. Looks like a good move to get out of PATH because of the massive competition in that area. This stock does not look like they have much competition except for the pills that have a safety concern and drugs being sold to addicts. This seems like a preventive measure so people getting the pills will not be able to sell them. If they banned the pills to most people, than this would be a massive stock. If the US wants to try to stop drugs from being illegally prescribed and sold, then this seems to be a very good product to curb that problem. NAVB is being manipulated by the HUGE short percentage. With the ADCOM vote coming in 3 weeks or so, I just wonder which direction the manipulators will run the price in the next two weeks.
As you say, wo a catalyst, could go lower, but bigger buys are coming including what looks to be one buy of about 300k split up into about 10-15 smaller buys all at once - tells me there is someone out there who knows their stuff who believes this is the bottom.